Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.50 |
| ▸ | MAP3K11 | Q16584 | 2/20 | 0.46 |
| ▸ | IKBKB | O14920 | 1/20 | 0.45 |
| ▸ | AKT1 | P31749 | 1/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.42 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.42 |
| ▸ | EGFR | P00533 | 2/20 | 0.42 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.42 |
| ▸ | LCK | P06239 | 2/20 | 0.42 |
| ▸ | FYN | P06241 | 2/20 | 0.42 |
| ▸ | AXL | P30530 | 2/20 | 0.42 |
| ▸ | FLT4 | P35916 | 2/20 | 0.42 |
| ▸ | KDR | P35968 | 2/20 | 0.42 |
| ▸ | FLT3 | P36888 | 2/20 | 0.42 |
| ▸ | FRK | P42685 | 2/20 | 0.42 |
| ▸ | CLK2 | P49760 | 2/20 | 0.42 |
| ▸ | CAMK2B | Q13554 | 2/20 | 0.42 |
| ▸ | CAMK2G | Q13555 | 2/20 | 0.42 |
| ▸ | CAMK2D | Q13557 | 2/20 | 0.42 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3347533 | 0.85 | MAP3K11 (0.46) | MAP3K11AKT1DYRK1APRKD3EGFR | |
| SCHEMBL3353465 | 0.83 | MAP3K11 (0.47) | MAP3K11AKT1DYRK1APRKD3EGFR | |
| SCHEMBL4376699 | 0.79 | AKT1 (0.63) | AKT1DYRK1APRKD3FLT3CLK2 | |
| SCHEMBL3348407 | 0.78 | JAK2 (0.52) | JAK2MAP3K11CDK2MAPK1CCNT1 | |
| SCHEMBL8940681 | 0.76 | MAP3K11 (0.68) | JAK2MAP3K11IKBKBAKT1DYRK1A | |
| SCHEMBL8940925 | 0.74 | JAK2 (0.51) | JAK2MAP3K11AKT1DYRK1APRKD3 | |
| SCHEMBL3349917 | 0.74 | AKT1 (0.44) | MAP3K11IKBKBAKT1DYRK1APRKD3 | |
| SCHEMBL28489988 | 0.73 | JAK2 (0.48) | JAK2MAP3K11DYRK1APRKD3EGFR | |
| SCHEMBL12663473 | 0.71 | SGK1 (0.65) | DYRK1APRKD3EGFRNTRK1LCK | |
| SCHEMBL8941846 | 0.69 | JAK2 (0.58) | JAK2DYRK1APRKD3NTRK1CLK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180370966-A1 | METHODS OF TREATMENT USING PYRIDINONYL PDK1 INHIBITORS | SUNESIS PHARMACEUTICALS, INC. | 2018-12-27 | — | — | US | disclosed |
| US-9873693-B2 | Methods of treatment using pyridinonyl PDK1 inhibitors | SUNESIS PHARMACEUTICALS, INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-8778977-B2 | Pyridinonyl PDK1 inhibitors | SUNESIS PHARMACEUTICALS, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| EP-2038272-B1 | PYRIDINONYL PDK1 INHIBITORS | SUNESIS PHARMACEUTICALS INC (US) | 2013-09-04 | — | — | EP | disclosed |
| US-20100144730-A1 | PYRIDINONYL PDK1 INHIBITORS | SUNESIS PHAMACEUTICALS (US) | 2010-06-10 | — | — | US | disclosed |
| EP-2038272-A2 | PYRIDINONYL PDK1 INHIBITORS | Sunesis Pharmaceuticals, Inc. (US) | 2009-03-25 | — | — | EP | disclosed |
| WO-2008005457-A2 | PYRIDINONYL PDK1 INHIBITORS | SUNESIS PHARMACEUTICALS (US) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180370966-A1 | METHODS OF TREATMENT USING PYRIDINONYL PDK1 INHIBITORS | PDK1, PDK2, PDK3 | JAK2 1237/4885MAP3K11 139/4885IKBKB 1112/4885 |
| US-20100144730-A1 | PYRIDINONYL PDK1 INHIBITORS | PDK1, PDK2, PDK3 | JAK2 1412/4885MAP3K11 95/4885IKBKB 1026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.